Morgan Stanley analyst Jeffrey Hung upgraded Amicus to Overweight from Equal Weight with a price target of $20, up from $15. The company has achieved each of its major goals, such as approval of Pombiliti plus Opfolda, over the last year and the firm expects the company to reach non-GAAP profitability by year-end, the analyst tells investors. The firm thinks Amicus is well-positioned for the Galafold and Pombiliti plus Opfolda launches, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FOLD:
- Amicus executive chairman John Crowley to step down
- Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
- Amicus files to sell 2.47M shares of common stock for holders
- Amicus reports Q3 EPS (7c), consensus (8c)
- Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
